Blue Matter Blog

The Psychedelic Renaissance: Opportunities & Challenges from Discovery Sessions 2024
May 15, 2024

What do you think of when you think of psychedelics? Groovy, oscillating patterns and hippies on drugs? What about a ketamine-assisted therapy clinic, or patients who are overcoming their post-traumatic stress disorder (PTSD) and treatment-resistant depression? Increasingly, the clinical benefits of psychedelic medicines are moving to the forefront as further research is conducted and societal …

The “Best Practice Organization,” Part 5: Measuring Impact
May 13, 2024

For a biopharma company to be a Best Practice Organization (BPO), it must develop frameworks for measuring the impact of its activities. In this series about what it takes to be a BPO, we have previously examined the importance of having clear vision, mission, and values; capabilities; and ways of working. As valuable as those …

Key Themes from ISPOR 2024
May 10, 2024

Greetings from Atlanta, where the 2024 annual meeting of ISPOR brought the best and brightest in the health economics and outcomes research (HEOR) field together from May 5-8. Blue Matter sent a team to attend and check out the cutting-edge research presented at the conference. While there, our team was treated to a sampling of …

Biotech in the UK: Successful Stakeholder Relations
May 3, 2024

Summary This spring, Blue Matter’s London team hosted the third meeting of the UK Biotech Club for C-suite leaders representing 20 London-based biotech companies. The leaders shared their perspectives on the outlook for the UK’s biotech sector and keys to succeed in a competitive industry. Conversation focused on how managing stakeholder relations, particularly with investors …